title: Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.
abstract: The objective of this review was to assess models of cost effectiveness for Parkinson's disease (PD) published after July 2002 and to derive recommendations for future modelling. A systematic literature search was performed in the databases PubMed, Current Contents, EMBASE, EconLit, the Cochrane Database of Systematic Reviews, and DARE (Database of Abstracts of Reviews of Effectiveness), NHS EED (Economic Evaluation Database) and HTA (Health Technology Assessment) of the UK NHS Centre for Review and Dissemination (July 2002 to March 2010). Only fully published studies using decision trees, Markov models, individual simulation models or sets of mathematical equations were included. Most of the 11 studies identified used Markov models (n = 9) and two employed were based on decision trees. Based on the Hoehn & Yahr (HY) scale, authors evaluated the cost effectiveness of drug treatments (n = 6), surgical approaches such as deep brain stimulation (n = 1) or striatal cell grafting (n = 1), and diagnostic procedures such as single photon emission computed tomography (SPECT) testing (n = 3) over a time horizon of 1 year to lifetime. Costs were adapted to address a societal and/or healthcare provider/third-party payer perspective. All but one of the interventions investigated were considered cost effective or cost saving. Cost-effectiveness modelling in PD between 2003 and 2010 showed only minor improvement when compared with our earlier review of models published from 1998 up to 2003. Cost-effectiveness modelling recommendations were complied with to only a limited extent, leaving room for quality improvement. More advanced modelling approaches may, so far, be under-represented, but may be used in the future, driven by the research question. Adverse events of treatment, co-morbidities or disease complications are not yet sufficiently included in the models to adequately represent clinical reality.
authors.affiliation: Department of Neurology, Philipps-University, Marburg, Germany.
authors.forename: Judith
authors.initials: J
authors.lastname: Dams
authors.forename: Bernhard
authors.initials: B
authors.lastname: Bornschein
authors.forename: Jens Peter
authors.initials: JP
authors.lastname: Reese
authors.forename: Annette
authors.initials: A
authors.lastname: Conrads-Frank
authors.forename: Wolfgang H
authors.initials: WH
authors.lastname: Oertel
authors.forename: Uwe
authors.initials: U
authors.lastname: Siebert
authors.forename: Richard
authors.initials: R
authors.lastname: Dodel
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D003362:Cost-Benefit Analysis / Q000379:methods / Q000706:statistics & numerical data; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D018803:Models, Economic; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics* / Q000628:therapy
chemical_list: D000978:Antiparkinson Agents
references.citation: Arch Neurol. 2004 Apr;61(4):561-6
references.pmid: 15096406
references.citation: Pharmacoeconomics. 1998 Sep;14(3):299-312
references.pmid: 10186468
references.citation: Neurology. 2001 Nov;57(10 Suppl 3):S34-8
references.pmid: 11775598
references.citation: Neurology. 2005 Jan 25;64(2):216-23
references.pmid: 15668416
references.citation: Value Health. 2003 Jan-Feb;6(1):9-17
references.pmid: 12535234
references.citation: Arch Neurol. 2011 Feb;68(2):165
references.pmid: 20937936
references.citation: Arch Neurol. 2002 Dec;59(12):1937-43
references.pmid: 12470183
references.citation: Arch Neurol. 2004 Jul;61(7):1044-53
references.pmid: 15262734
references.citation: Neurology. 2004 Mar 23;62(6):937-42
references.pmid: 15037696
references.citation: Aust New Zealand Health Policy. 2009 Jun 24;6:15
references.pmid: 19549341
references.citation: Pharmacoeconomics. 2002;20(9):617-28
references.pmid: 12141889
references.citation: Lancet. 2005 Mar 12-18;365(9463):947-54
references.pmid: 15766996
references.citation: Br J Psychiatry. 2003 Dec;183:498-506
references.pmid: 14645020
references.citation: Pharmacoeconomics. 2005;23(8):817-36
references.pmid: 16097843
references.citation: Ann Neurol. 1984 Sep;16(3):278-82
references.pmid: 6333204
references.citation: Pharmacoeconomics. 2004;22(12):759-69
references.pmid: 15294010
references.citation: Neurologia. 2009 May;24(4):220-9
references.pmid: 19603291
references.citation: Neurology. 2001 Jun;56(11 Suppl 5):S1-S88
references.pmid: 11402154
references.citation: N Engl J Med. 2007 Jan 4;356(1):29-38
references.pmid: 17202453
references.citation: Pharmacoeconomics. 2002;20(12):855-67
references.pmid: 12236807
references.citation: Mov Disord. 2003 Jan;18(1):19-31
references.pmid: 12518297
references.citation: Neurol Clin. 1992 May;10(2):331-9
references.pmid: 1584177
references.citation: Mov Disord. 2003 Oct;18 Suppl 7:S52-62
references.pmid: 14531047
references.citation: J Neurol Neurosurg Psychiatry. 1999 Sep;67(3):300-7
references.pmid: 10449550
references.citation: Adv Neurol. 1996;69:3-11
references.pmid: 8615142
references.citation: N Engl J Med. 2000 May 18;342(20):1484-91
references.pmid: 10816186
references.citation: Br Med J (Clin Res Ed). 1986 Feb 22;292(6519):534-6
references.pmid: 2936423
references.citation: Pharmacoeconomics. 2003;21(13):941-50
references.pmid: 12959626
references.citation: Age Ageing. 1999 Mar;28(2):99-102
references.pmid: 10350403
references.citation: Mov Disord. 2003 Oct;18(10):1139-45
references.pmid: 14534917
references.citation: Drugs. 1998;55 Suppl 1:23-30
references.pmid: 9483167
references.citation: JAMA. 2000 Oct 18;284(15):1931-8
references.pmid: 11035889
references.citation: J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
references.pmid: 1564476
references.citation: Brain. 2002 Apr;125(Pt 4):861-70
references.pmid: 11912118
references.citation: Parkinsonism Relat Disord. 2003 Jan;9(3):163-8
references.pmid: 12573872
references.citation: Ann Pharmacother. 2006 Apr;40(4):651-7
references.pmid: 16569799
references.citation: Value Health. 2004 Sep-Oct;7(5):610-26
references.pmid: 15367256
references.citation: Neurology. 2000;54(11 Suppl 4):S21-5
references.pmid: 10854348
references.citation: Mov Disord. 2003 Aug;18(8):898-905
references.pmid: 12889079
references.citation: J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9
references.pmid: 12876237
references.citation: Value Health. 2001 Jul-Aug;4(4):316-28
references.pmid: 11705299
references.citation: Neurology. 1998 Nov;51(5):1309-14
references.pmid: 9818851
references.citation: J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):67-73
references.pmid: 10864606
references.citation: Acta Neurol Scand. 2001 Dec;104(6):343-8
references.pmid: 11903087
references.citation: Drugs Aging. 2009;26(9):791-801
references.pmid: 19728752
references.citation: Neurol Clin. 2009 Aug;27(3):633-77, v
references.pmid: 19555825
references.citation: J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):308-12
references.pmid: 10945804
references.citation: Mov Disord. 2000 May;15(3):503-10
references.pmid: 10830416
references.citation: Expert Rev Pharmacoecon Outcomes Res. 2002 Apr;2(2):91-7
references.pmid: 19807321
references.citation: BMJ. 2006 Mar 25;332(7543):699-703
references.pmid: 16495332
references.citation: Acta Neurol Scand. 1995 Dec;92(6):443-50
references.pmid: 8750108
references.citation: Parkinsonism Relat Disord. 2011 May;17(4):265-9
references.pmid: 21310647
references.citation: Appl Health Econ Health Policy. 2009;7(3):167-80
references.pmid: 19799471
references.citation: Eur J Health Econ. 2003;4(1):37-42
references.pmid: 15609167
references.citation: Can J Neurol Sci. 1991 Aug;18(3):275-8
references.pmid: 1913360
references.citation: Curr Med Res Opin. 2005 Jul;21(7):1005-14
references.pmid: 16004667
references.citation: Pharmacoeconomics. 1999 Jul;16(1):59-69
references.pmid: 10539122
references.citation: Mov Disord. 2002 Nov;17(6):1213-20
references.pmid: 12465059
references.citation: Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1367-76
references.pmid: 18385998
references.citation: Lancet. 2002 May 4;359(9317):1589-98
references.pmid: 12047983
references.citation: Ann Neurol. 1997 Nov;42(5):747-55
references.pmid: 9392574
references.citation: Parkinsonism Relat Disord. 2006 Oct;12(7):443-52
references.pmid: 16798054
references.citation: CNS Drugs. 2008;22(10):841-60
references.pmid: 18788836
references.citation: Mov Disord. 2000 Nov;15(6):1112-8
references.pmid: 11104193
references.citation: Mov Disord. 2008 Nov 15;23(15):2202-9
references.pmid: 18785639
references.citation: Qual Life Res. 2000;9(7):819-27
references.pmid: 11297024
references.citation: Neurology. 2001 Oct 23;57(8):1497-9
references.pmid: 11673599
references.citation: Biostatistics. 2009 Oct;10(4):729-43
references.pmid: 19648228
references.citation: Nat Neurosci. 2002 Jul;5(7):627-8
references.pmid: 12042822
references.citation: Eur J Health Econ. 2003;4(2):70-8
references.pmid: 15609171